{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-290473","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2026-06-30T20:05:15+00:00","discovered_at":"2026-06-30T20:06:00.270601+00:00","generated_at":"2026-06-30T20:06:32.525355+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptevo awarded $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling studies","bullets":["Grant of $1,499,951 from Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling studies for APVO451, a trispecific antibody targeting nectin-4, CD40, and CD3 for solid tumors.","Funding is non-dilutive and on a reimbursement basis; project period through June 2028, subject to milestones and matching contributions.","APVO451 advancing toward development candidate selection by year-end 2026 and IND-enabling studies in Q1 2027.","Grant provides external validation of APVO451's trispecific design and supports Aptevo's solid tumor immunotherapy efforts.","Aptevo retains IP ownership; grant includes customary terms including acknowledgment and commercialization commitments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-290473","json":"https://secwatch.observer/filing/0001193125-26-290473.json","markdown":"https://secwatch.observer/filing/0001193125-26-290473.md","text":"https://secwatch.observer/filing/0001193125-26-290473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526290473/0001193125-26-290473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526290473/apvo-20260629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T20:06:32.525355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}